文献速递心外重症与机械循环支持

衰弱对当代耐久性机械循环支持桥接心脏移植受者死亡率和并发症的影响

Impact of frailty on mortality and morbidity in bridge to transplant recipients of contemporary durable mechanical circulatory support.
PubMed 文献 · J Heart Lung Transplant · 2022-02-19

研究纳入96例左心室辅助装置(LVAD)和11例双心室支持(BiV)桥接移植患者,评估衰弱对术后结局的影响。衰弱LVAD患者360天死亡率与非衰弱者无显著差异,但衰弱BiV患者死亡率显著高于非衰弱BiV患者;衰弱患者ICU和住院时间更长;多数衰弱患者术后转为非衰弱。

要点

  • 衰弱定义:FFP≥3个躯体域或FFP≥2个躯体域加MoCA认知障碍。
  • 衰弱LVAD患者360天死亡率15.8% vs 非衰弱6.9%,无显著差异(p=0.19)。
  • 衰弱BiV患者死亡率4/5 vs 非衰弱BiV 0/6,差异显著(p=0.013)。

核心结论

  • 衰弱标志物异常在桥接移植耐久性机械循环支持患者中常见,所用标志物可预测BiV支持患者死亡率,但不能预测LVAD患者死亡率。
  • 这些发现可能有助于识别最受益于BiV桥接移植治疗的患者。

研究设计与样本

  • 研究纳入接受左心室辅助装置(LVAD,n=96)或双心室支持(BiV,n=11)作为桥接移植的患者,进行衰弱评估。
  • 衰弱定义为Fried衰弱表型(FFP)≥3个躯体域,或FFP≥2个躯体域加蒙特利尔认知评估(MoCA)认知障碍。

主要发现

  • 衰弱LVAD患者360天死亡6/38(15.8%) vs 非衰弱LVAD患者4/58(6.9%),p=0.19,无显著差异。
  • 衰弱BiV患者死亡4/5 vs 非衰弱BiV患者0/6,p=0.013,衰弱BiV患者死亡率显著增高。
  • 全部患者中,衰弱患者较非衰弱患者ICU停留时间延长,12 vs 6天(p<0.0001);住院时间延长,48 vs 27天(p<0.0001)。
  • 血液相容性和感染相关不良事件无差异。
  • 衰弱患者中多数(22/29,75.9%)在MCS后转为非衰弱;非衰弱患者中少数(3/42,7.1%)转为衰弱(p=0.0003)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty is associated with adverse outcomes in advanced heart failure. We studied the impact of frailty on postoperative outcomes in bridge to transplant (BTT) durable mechanical circulatory support (MCS) recipients. METHODS: Patients undergoing left ventricular assist device (LVAD, n = 96) or biventricular support (BiV, n = 11) as BTT underwent frailty assessment. Frailty was defined as ≥ 3 physical domains of the Fried's Frailty Phenotype (FFP) or ≥ 2 physical domains of the FFP plus cognitive impairment on the Montreal Cognitive Assessment (MoCA). RESULTS: No difference in mortality at 360 days was observed in frail (n = 6/38, 15.8%) vs non-frail (n = 4/58, 6.9%) LVAD supported patients, p = 0.19. However, there was a significant excess mortality in frail BiV (n = 4/5) vs non-frail BiV (n = 0/6) supported patients, p = 0.013. In all patients, frail patients compared to non-frail patients experienced longer intensive care unit stay, 12 vs 6 days (p < 0.0001) and hospital length of stay, 48 vs 27 days (p < 0.0001). There was no difference in hemocompatibility and infection related adverse events. The majority (n = 22/29, 75.9%) of frail patients became non-frail following MCS; contrastingly, a minority (n = 3/42, 7.1%) became frail from being non-frail (p = 0.0003). CONCLUSIONS: Abnormal markers of frailty are common in patients undergoing BTT-MCS support and those used herein predict mortality in BiV-supported patients, but not in LVAD patients. These findings may help us better identify patients who will benefit most from BiV-BTT therapy.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Muthiah K, Wilhelm K, Robson D, et al. Impact of frailty on mortality and morbidity in bridge to transplant recipients of contemporary durable mechanical circulatory support. J Heart Lung Transplant. 2022. PMID: 35418322. doi:10.1016/j.healun.2022.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。